Amgen Cites Osteoporosis Injectable’s Efficacy Over Fosamax In Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Company presents preliminary Phase II results for AMG 162 that show a significantly greater total hip bone mineral density compared to Merck’s Fosamax; changes in lower spine BMD were comparable between the two agents. Amgen has initiated registration for a Phase III study.